Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Lemairamin and Phenylpiracetam hydrazide — mechanism, side effects, legal status, and pricing.
Lemairamin is a non-peptide small-molecule cinnamamide alkaloid (N-phenethyl cinnamide) natural product, not approved for human use in any jurisdiction. All available data are preclinical (rodent, zebrafish, C. elegans, in vitro, and computational). It is sold exclusively as an unregulated 'research chemical' explicitly labeled 'not for human consumption'; quality, purity, and identity are not independently verified by any regulatory body. No human clinical trials, pharmacokinetic studies, or safety data exist.
Phenylpiracetam hydrazide is a non-peptide racetam-class small molecule — specifically a pyrrolidinone acetohydrazide in which the terminal carboxamide of phenylpiracetam (fonturacetam) is replaced by a carbohydrazide group. First synthesized in 1980 by a Russian medicinal-chemistry group screening 4-phenyl-2-pyrrolidinone derivatives for anticonvulsant activity, it has never been approved as a drug in any jurisdiction and has no human clinical trial data. The parent compound phenylpiracetam is explicitly listed on the WADA Prohibited List under S6.A (Non-Specified Stimulants); the hydrazide analog's own it is not on the WADA Prohibited List (only beta-2 agonists are prohibited, Category S3). It is sold by gray-market research-chemical vendors labeled 'not for human consumption.'
Lemairamin
Phenylpiracetam hydrazide
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Lemairamin
No pricing data yet.
Check Lemairamin prices →Phenylpiracetam hydrazide
No pricing data yet.
Check Phenylpiracetam hydrazide prices →COA corpus from Disclosed Labs — independently tested batches only.
Lemairamin
2
COAs
99.8%
Avg purity
2
Labs
Phenylpiracetam hydrazide
2
COAs
99.4%
Avg purity
2
Labs
No human data exist. No completed or registered human clinical trials were located on ClinicalTrials.gov, and no PubMed-indexed human pharmacokinetic, safety, or efficacy studies exist. All available data are preclinical: In transgenic Alzheimer's mice, gx-50 disassembled Aβ oligomers, decreased cortical Aβ accumulation, inhibited Aβ-induced neuronal apoptosis and calcium toxicity, improved Morris water maze performance, and was reported to cross the blood-brain barrier (Tang et al. 2013). In mouse and rat pain models (formalin tonic, neuropathic, bone-cancer pain), subcutaneous and intrathecal lemairamin dose-dependently reduced pain hypersensitivity/mechanical allodynia without evident tolerance, linked to spinal α7 nAChR activation and downstream IL-10/β-endorphin release (Wang et al. 2020). Murine microglial cell cultures showed gx-50 activation of α7 nAChR engaged JAK2/STAT3 and PI3K/AKT signaling to suppress pro-inflammatory cytokine secretion (Shi et al. 2016). Zebrafish DSS-induced colitis models showed lemairamin attenuated intestinal inflammation via Akt signaling (2024). C. elegans studies reported WGX-50 promoted markers of healthy ageing (daf-16/skn-1 longevity genes, 2025).
Key references
No human clinical trials have been conducted; no ClinicalTrials.gov record or DrugBank entry exists. The sole preclinical finding is from the 1980 Glozman et al. synthesis paper: an ED<sub>50</sub> of approximately 310 mg/kg for seizure protection in a rodent electroshock assay (species, strain, sex, and route not fully recoverable from accessed sources). No published human toxicology, LD<sub>50</sub>, pharmacokinetics, or adverse-event data were located for this compound.
Lemairamin and Phenylpiracetam hydrazide are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs